Quantcast

Effective combination of methylprednisolone and interferon β-secreting mesenchymal stem cells in a model of multiple sclerosis

Research paper by Mi Jin Kim, Jung Yeon Lim; Soon A. Park; Sang In Park; Won Shik Kim; Chung Heon Ryu; Sin-Soo Jeun

Indexed on: 05 Dec '17Published on: 03 Dec '17Published in: Journal of Neuroimmunology



Abstract

Publication date: Available online 29 November 2017 Source:Journal of Neuroimmunology Author(s): Mi Jin Kim, Jung Yeon Lim, Soon A. Park, Sang In Park, Won Shik Kim, Chung Heon Ryu, Sin-Soo Jeun Methylprednisolone (MP) has been recommended as a standard drug in MS therapies. We previously demonstrated that IFNβ-secreting human bone marrow-derived mesenchymal stem cells (MSCs-IFNβ) exert immunomodulatory effects in experimental autoimmune encephalomyelitic (EAE) mice. In this study, we evaluated whether a combined treatment of MP and MSCs-IFNβ had enhanced therapeutic effects on EAE mice. The combination treatment resulted in enhanced immunomodulatory effects, including reduced production of pro-inflammatory cytokines and increased production of anti-inflammatory cytokines. Thus, our results provide a framework for designing novel experimental protocols to enhance the therapeutic effects of existing MS treatments. Graphical abstract